Misonix receives another Nasdaq deficiency letter

Therapeutic ultrasound developer Misonix has received another deficiency letter from the Nasdaq Stock Market for delinquency in submitting quarterly reports.

Misonix has been informed that it is not in compliance with Nasdaq rules for continued listing due to an inability to file its quarterly report on Form 10-Q for the second quarter (end-December 31) by the February 9 deadline, as well as the company's ongoing failure to file its quarterly report for its fiscal first quarter (end-September 30). Nasdaq initially sent Misonix a deficiency letter in November for delays in filing its quarterly and annual reports.

In accordance with a plan previously approved by Nasdaq, the stock market has given Misonix until March 13 to regain compliance with its listing rules. Misonix must also submit an update to the original compliance plan by February 27.

The firm did file its Form 10-K on February 9 for the fiscal year ended June 30, 2016, and Misonix said that its management believes it will be able to file the delinquent quarterly reports no later than March 13.

Page 1 of 507
Next Page